SPECT/PET Findings in Lewy Body Dementia

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-642-54307-4_17
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo

  2012cited by this paper
• Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT

  2012cited by this paper
• Brain amyloid and cognition in Lewy body diseases

  2012cited by this paper
• Thalamic cholinergic innervation is spared in Alzheimer disease compared to parkinsonian disorders.

  2012cited by this paper
• Differential Diagnosis in Alzheimer’s Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging

  2012cited by this paper
• EFNS task force: the use of neuroimaging in the diagnosis of dementia

  2012cited by this paper
• Imaging of Microglia in Patients with Neurodegenerative Disorders

  2012cited by this paper
• Multimodality imaging characteristics of dementia with Lewy bodies.

  2012cited by this paper
• In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease

  2011cited by this paper
• Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias

  2011cited by this paper
• Dopaminergic imaging: clinical utility now and in the future

  2011cited by this paper
• Mechanisms underlying inflammation in neurodegeneration.

  2010cited by this paper
• Typical cerebral metabolic patterns in neurodegenerative brain diseases

  2010cited by this paper
• Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo

  2010cited by this paper
• Amyloid imaging of Lewy body‐associated disorders

  2010cited by this paper
• Improved Visual Hallucination by Donepezil and Occipital Glucose Metabolism in Dementia with Lewy Bodies: The Osaki-Tajiri Project

  2010cited by this paper
• Nicotinic 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in Alzheimer's disease and dementia with Lewy bodies.

  2010cited by this paper
• Covariance 99mTc-Exametazime SPECT Patterns in Alzheimer’s Disease and Dementia with Lewy Bodies: Utility in Differential Diagnosis

  2010cited by this paper
• Differential Diagnosis of Dementia with Lewy Bodies and Alzheimer Disease Using Combined MR Imaging and Brain Perfusion Single-Photon Emission Tomography

  2010cited by this paper
• [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?

  2010cited by this paper
• Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies

  2009cited by this paper
• Efficacy of Single Photon Emission Computed Tomography in Differentiating Dementia with Lewy Bodies - A Review of Neurotransmitter and Perfusion Imaging

  2009cited by this paper
• Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics.

  2009cited by this paper
• Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET

  2009cited by this paper
• The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-β-CIT SPECT for Diagnosis of Dementia with Lewy Bodies

  2009cited by this paper
• Microglial activation and amyloid deposition in mild cognitive impairment

  2009cited by this paper
• Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: A 123I‐FP‐CIT SPECT study

  2009cited by this paper
• Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.

  2009cited by this paper
• Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies

  2009cited by this paper
• "Parkinson-dementia" diseases: a comparison by double tracer SPECT studies.

  2009cited by this paper
• Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106.

  2008cited by this paper
• Cellular glutathione peroxidase in human brain: cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson’s disease and dementia with Lewy bodies

  2008cited by this paper
• Imaging amyloid deposition in Lewy body diseases

  2008cited by this paper
• Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation

  2008cited by this paper
• A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies

  2008cited by this paper
• The Positron Emission Tomography Ligand DAA1106 Binds With High Affinity to Activated Microglia in Human Neurological Disorders

  2008cited by this paper
• Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography

  2008cited by this paper
• Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study.

  2008cited by this paper
• Nicotinic α4β2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations

  2008cited by this paper
• Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias

  2008cited by this paper
• Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro.

  2008cited by this paper
• Usefulness of a blood flow analyzing program 3DSRT to detect occipital hypoperfusion in dementia with Lewy bodies.

  2008cited by this paper
• Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)‐[11C]dihydrotetrabenazine positron emission tomography

  2008cited by this paper
• A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies

  2007cited by this paper
• Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase.

  2007cited by this paper
• Imaging β-amyloid burden in aging and dementia

  2007cited by this paper
• Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy

  2007cited by this paper
• Evaluation of brain perfusion SPECT using an easy Z-score imaging system (eZIS) as an adjunct to early-diagnosis of neurodegenerative diseases.

  2007cited by this paper
• Comparison of Regional Brain Volume and Glucose Metabolism Between Patients with Mild Dementia with Lewy Bodies and Those with Mild Alzheimer's Disease

  2007cited by this paper
• Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies

  2007cited by this paper
• Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

  2007cited by this paper
• PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis.

  2007cited by this paper
• Evaluation of Probable or Possible Dementia with Lewy Bodies Using 123I-IMP Brain Perfusion SPECT, 123I-MIBG, and 99mTc-MIBI Myocardial SPECT

  2007cited by this paper
• Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies

  2007cited by this paper
• A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies

  2007cited by this paper
• Cognitive, affective, and psychiatric features of Parkinson's disease.

  2006cited by this paper
• In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in progressive supranuclear palsy

  2006cited by this paper
• Differentiation of dementia with Lewy bodies from Alzheimer's disease using Mini-Mental State Examination and brain perfusion SPECT.

  2006cited by this paper
• Vesicular monoamine transporter 2: Role as a novel target for drug development

  2006cited by this paper
• Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB

  2006cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop

  2006cited by this paper
• Differences in neuropathologic characteristics across the Lewy body dementia spectrum

  2006cited by this paper
• Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

  2006cited by this paper
• In vivo SPECT imaging of muscarinic acetylcholine receptors using (R, R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia

  2006cited by this paper
• Brain 3D-SSP SPECT analysis in dementia with Lewy bodies, Parkinson's disease with and without dementia, and Alzheimer's disease.

  2005cited by this paper
• Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson’s disease with and without dementia assessed using 123I-FP-CIT SPECT

  2005cited by this paper
• Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing.

  2005cited by this paper
• Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies.

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Differentiation of Dementia with Lewy Bodies from Alzheimer’s Disease Using Brain SPECT

  2005cited by this paper
• Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients

  2005cited by this paper
• Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies

  2005cited by this paper
• Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study

  2005cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease

  2004cited by this paper
• Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease

  2004cited by this paper
• Rivastigmine for dementia associated with Parkinson's disease.

  2004cited by this paper
• Role of Cholinesterase Inhibitors in Parkinson’s Disease and dementia with Lewy Bodies

  2004cited by this paper
• Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.

  2004cited by this paper
• 99mTc-HMPAO and 99mTc-ECD perform differently in typically hypoperfused areas in Alzheimer's disease

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Regional cerebral blood flow in Parkinson's disease with and without dementia

  2003cited by this paper
• Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease

  2003cited by this paper
• Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.

  2003cited by this paper
• Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer’s disease

  2003cited by this paper
• Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains

  2003cited by this paper
• Neuroinflammation : mechanisms and management

  2003cited by this paper
• Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

  2002cited by this paper
• Worsening of motor function and mood in a patient with Parkinson's disease after pharmacologic challenge with oral rivastigmine.

  2002cited by this paper
• PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects

  2002cited by this paper
• Value of 99mTc-ECD SPET for the diagnosis of dementia with Lewy bodies

  2002cited by this paper
• A comparison of 99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping

  2002cited by this paper
• Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD

  2001cited by this paper
• Neurones and microglia in central nervous system immune response to degenerative processes. Part 1: Alzheimer's disease and Lewy body variant of Alzheimer's disease. Quantitative study.

  2001cited by this paper
• Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales

  2001cited by this paper
• Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

  2001cited by this paper
• Occipital Glucose Metabolism in Dementia with Lewy Bodies with and without Parkinsonism: A Study Using Positron Emission Tomography

  2001cited by this paper
• The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.

  2000cited by this paper
• 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies

  2000cited by this paper
• Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

  2000cited by this paper

• Detection of Alzheimer’s Disease Based on Cloud-Based Deep Learning Paradigm

  2023cites this paper
• Alzheimer’s Diseases Detection by Using Deep Learning Algorithms: A Mini-Review

  2020cites this paper
• PET in Neurological and Psychiatric Disorders: Technologic Advances and Clinical Applications

  2017cites this paper